Is AmBisome associated with infusion-related reactions and how do they compare with those of amphotericin B deoxycholate?
In Study 94-0-002, the large, double-blind study of pediatric and adult febrile neutropenic patients, no premedication to prevent infusion-related reaction was administered prior to the first dose of study drug (Day 1). AmBisome-treated patients had a lower incidence of infusion-related fever (17% versus 44%), chills/rigors (18% versus 54%) and vomiting (6% versus 8%) on Day 1 as compared to amphotericin B deoxycholate-treated patients. The percentage of patients who received drugs either for the treatment or prevention of infusion-related reactions (e.g., acetaminophen, diphenhydramine, meperidine and hydrocortisone) was lower in AmBisome-treated patients compared with amphotericin B deoxycholate-treated patients. There have been a few reports of flushing, back pain with or without chest tightness, and chest pain associated with AmBisome administration; on occasion this has been severe. Where these symptoms were noted, the reaction developed within a few minutes after the start of inf
Related Questions
- What are the most frequent adverse reactions associated with AmBisome therapy and how do they compare with those of amphotericin B deoxycholate?
- How do goose-hunting and associated land values compare between Talcot and Lac qui Parle?
- How does AmBisome compare with Abelcet® in terms of infusion-related reactions (IRR)?
